Attached files
| file | filename |
|---|---|
| EX-10.22 - EX-10.22 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d22.htm |
| 10-K - 10-K - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231x10k.htm |
| EX-32.1 - EX-32.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex31d1.htm |
| EX-23.1 - EX-23.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex23d1.htm |
| EX-21.1 - EX-21.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex21d1.htm |
| EX-10.34 - EX-10.34 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d34.htm |
| EX-10.33 - EX-10.33 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d33.htm |
| EX-10.23 - EX-10.23 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d23.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark Ragosa, Interim Chief Financial Officer of Kiniksa Pharmaceuticals, Ltd. (the “Company”), hereby certify pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Annual Report on Form 10-K of the Company for the period ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: February 25, 2021 | /s/ Mark Ragosa |
| Mark Ragosa |
| Interim Chief Financial Officer (Principal Financial Officer) |
| |
1